Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR) Formulation 11mg Once Daily (QD) and Tofacitinib Immediate Release (IR) Formulation 5 mg Twice Daily (BID) Within a United States (US) Healthcare Claims Database
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Tofacitinib (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Apr 2024 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT04018001 )
- 19 Oct 2020 New trial record
- 09 Oct 2020 Results published in the Advances in Therapy